Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Tokyo Court Strikes Down Baxalta Claim against Hemlibra: Chugai
March 29, 2018
- Janssen Files Japan NDA for Apalutamide in CRPC
March 29, 2018
- Eisai to Quit Generic Supply Biz, Transfer Subsidiary to Nichi-Iko
March 29, 2018
- Takeda Mulls Takeover Bid for Shire
March 29, 2018
- Sumitomo Dainippon to Transfer Back Office Staffers to Dedicated Subsidiary
March 28, 2018
- Tokyo Upstart Curadim In-Licenses Drug Candidate for IPF/NASH
March 28, 2018
- Sumitomo Dainippon, Carna Bio Cut Deal on Kinase Inhibitor Research in Psychiatry/Neurology
March 28, 2018
- Enfortumab Vedotin Gets FDA Breakthrough Status in Urothelial Cancer: Astellas/Seattle Genetics
March 28, 2018
- Zeria Obtains Japan Rights to Veltassa from Vifor Pharma
March 28, 2018
- Mitsubishi Tanabe Explores Creation of Drug Safety Info. Database with Drug Makers: President
March 28, 2018
- Daiichi Sankyo to Launch Open Innovation Research on Novel Cancer Hyperthermia Therapy with Academia, Venture Capital
March 28, 2018
- Opdivo Gains Label Expansion in South Korea: Ono
March 27, 2018
- Shionogi, Kyoto Univ. Ink Research Collaboration for Psychiatric Disorders
March 27, 2018
- Asahi Kasei in Licensing Pact with RaQualia to Begin Preclinical Development for Novel Neuropathic Pain Candidate
March 27, 2018
- Stem Cell Therapy Alofisel Wins European Approval: Takeda
March 27, 2018
- JCR Shooting for Big Chunk of 900 Billion Yen Global Lysosome Storage Disease Market with J-Brain Cargo
March 27, 2018
- Mitsubishi Tanabe Aims to Attain Efficiency in Clinical Trials through Full-Fledged Use of Hitachi’s AI Technology
March 27, 2018
- Japan Approves 1st Herceptin Biosimilar for Gastric Cancer
March 26, 2018
- Shionogi Partners with CARB-X to Fight CRE Superbug
March 23, 2018
- Thomas-Peter Hausner Named Next President of Bayer Holdings Japan
March 23, 2018
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…